ADA and leukemia: The occurrence of a secondary tumor (myelodysplasia followed by leukemia) in one SCD patient treated with LV30, likely as a result of chemotherapy-induced mutagenesis on residual host cells as well as a bone marrow dysplasia observed in an ADA-SCID patient treated with γRV deriving from non-corrected cells31 were not unexpected.